SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (BOLD) (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results